News
Public · Published
Lg Chem Signs $855 Million License-Out Agreement With Rhythm Pharmaceuticals
LG Chem Ltd signed a license-out agreement worth $855 million with Rhythm Pharmaceuticals. The deal includes an upfront payment of $450 million and a milestone payment of $405 million.
Published:
Updated:
What happened
LG Chem Ltd signed a license-out agreement worth $855 million with Rhythm Pharmaceuticals. The deal includes an upfront payment of $450 million and a milestone payment of $405 million.
Confirmed
Global impact / market context
This deal brings LG Chem $450 million in upfront cash, which can fund research or reduce borrowed money, while the $405 million milestone depends on future success. For Rhythm Pharmaceuticals, it adds a pipeline asset but raises its spending and risk.
Analyst inference
License-out deals let a company earn money by letting a partner develop and sell its drug, shifting costs and risk. Investors may weigh LG Chem's cash boost against Rhythm Pharmaceuticals' added costs and future payment obligations.
Analyst inference
What to watch
- LG Chem receives a $450 million upfront payment, which is cash paid at signing, and a $405 million milestone payment tied to future progress. Confirmed
- Watch for details on what the milestone payment requires, since conditions determine when and whether the $405 million is actually paid. Proposed
- Track Rhythm Pharmaceuticals' research and development spending and cash available, because upfront and milestone costs could affect its finances. Analyst inference
Evidence
- Original source link unavailable